ECHA has recommended that the European Commission should amend the REACH authorisation list to include endocrine disrupting properties for four DEHP, BBP, DBP, and DIBP.
If these changes are brought about, some previously exempted uses will require authorisation. These include the use of DEHP in food contact materials or medical devices.
Further recommendations from ECHA are that the exemption for DEHP in medicinal product packaging be removed and that authorisation should be required for any of the four DEHP present in mixtures at concentration above or equal to 0.1% by weight
CONTINUE READING ON www.europeanplasticisers.eu